HK1075664A1 - Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders - Google Patents

Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders

Info

Publication number
HK1075664A1
HK1075664A1 HK05110023A HK05110023A HK1075664A1 HK 1075664 A1 HK1075664 A1 HK 1075664A1 HK 05110023 A HK05110023 A HK 05110023A HK 05110023 A HK05110023 A HK 05110023A HK 1075664 A1 HK1075664 A1 HK 1075664A1
Authority
HK
Hong Kong
Prior art keywords
disorders
piperazine
treatment
benzothiazoles
agents
Prior art date
Application number
HK05110023A
Other languages
English (en)
Inventor
Pascale Gaillard
Jean-Pierre Gotteland
Pierre-Alain Vitte
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of HK1075664A1 publication Critical patent/HK1075664A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK05110023A 2002-04-25 2005-11-10 Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders HK1075664A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02100417 2002-04-25
PCT/EP2003/004323 WO2003091249A1 (en) 2002-04-25 2003-04-25 Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders

Publications (1)

Publication Number Publication Date
HK1075664A1 true HK1075664A1 (en) 2005-12-23

Family

ID=29265991

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05110023A HK1075664A1 (en) 2002-04-25 2005-11-10 Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders

Country Status (23)

Country Link
US (1) US7314878B2 (xx)
EP (1) EP1501828B1 (xx)
JP (1) JP4523289B2 (xx)
KR (1) KR100948469B1 (xx)
CN (1) CN1310911C (xx)
AT (1) ATE383356T1 (xx)
AU (1) AU2003233067B2 (xx)
BR (1) BRPI0309594A8 (xx)
CA (1) CA2481763C (xx)
CY (1) CY1107204T1 (xx)
DE (1) DE60318567T2 (xx)
DK (1) DK1501828T3 (xx)
EA (1) EA009682B1 (xx)
ES (1) ES2297165T3 (xx)
HK (1) HK1075664A1 (xx)
IL (2) IL164796A (xx)
MX (1) MXPA04010474A (xx)
PT (1) PT1501828E (xx)
RS (1) RS51407B (xx)
SI (1) SI1501828T1 (xx)
UA (1) UA78035C2 (xx)
WO (1) WO2003091249A1 (xx)
ZA (1) ZA200408023B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78035C2 (en) 2002-04-25 2007-02-15 Applied Research Systems Piperazine benzothiazole for treatment of cerebral ischemic disorders or cns disorders
CA2534314C (en) * 2003-09-12 2012-11-13 Applied Research Systems Ars Holding N.V. Benzothiazole derivatives for the treatment of diabetes
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
EA011614B1 (ru) * 2004-11-17 2009-04-28 Арес Трейдинг С.А. Препараты бензотиазола и их применение
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
BRPI0613042A2 (pt) * 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
WO2008125518A2 (en) * 2007-04-17 2008-10-23 Merck Serono S.A. Process for the preparation of piperazine benzothiazoles
CN102015689B (zh) * 2008-05-16 2014-01-08 霍夫曼-拉罗奇有限公司 Jnk的抑制剂
KR101800916B1 (ko) * 2010-06-04 2017-11-23 에프. 호프만-라 로슈 아게 Jnk 억제제로서 유용한 2-아미노-피리미딘 유도체
US8471027B2 (en) * 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
WO2014114186A1 (zh) * 2013-01-24 2014-07-31 山东亨利医药科技有限责任公司 Jnk抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4153574B2 (ja) 1997-09-10 2008-09-24 トーアエイヨー株式会社 新規なピペリジン誘導体、その製造法およびそれを含有する循環器官用剤
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
EP1193256A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
UA78035C2 (en) 2002-04-25 2007-02-15 Applied Research Systems Piperazine benzothiazole for treatment of cerebral ischemic disorders or cns disorders

Also Published As

Publication number Publication date
UA78035C2 (en) 2007-02-15
IL164796A0 (en) 2005-12-18
US20050261304A1 (en) 2005-11-24
DK1501828T3 (da) 2008-03-10
CA2481763C (en) 2011-06-14
CY1107204T1 (el) 2012-11-21
AU2003233067A1 (en) 2003-11-10
SI1501828T1 (sl) 2008-04-30
RS51407B (en) 2011-02-28
EA200401423A1 (ru) 2005-04-28
EA009682B1 (ru) 2008-02-28
AU2003233067B2 (en) 2009-01-08
ES2297165T3 (es) 2008-05-01
MXPA04010474A (es) 2004-12-13
JP2006504631A (ja) 2006-02-09
BRPI0309594A2 (pt) 2016-11-16
KR100948469B1 (ko) 2010-03-17
BRPI0309594A8 (pt) 2017-04-11
EP1501828A1 (en) 2005-02-02
WO2003091249A1 (en) 2003-11-06
RS92804A (xx) 2006-12-15
EP1501828B1 (en) 2008-01-09
PT1501828E (pt) 2008-02-11
CA2481763A1 (en) 2003-11-06
CN1662528A (zh) 2005-08-31
ZA200408023B (en) 2005-11-30
CN1310911C (zh) 2007-04-18
DE60318567D1 (de) 2008-02-21
US7314878B2 (en) 2008-01-01
DE60318567T2 (de) 2009-02-19
JP4523289B2 (ja) 2010-08-11
ATE383356T1 (de) 2008-01-15
IL164796A (en) 2013-02-28
KR20040104572A (ko) 2004-12-10

Similar Documents

Publication Publication Date Title
HK1075664A1 (en) Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders
HK1080467A1 (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
ATE524169T1 (de) Therapeutische strategien für die prävention und behandlung der alzeheimer-krankheit
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
MY135841A (en) Novel benzodioxoles
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
DK1242415T3 (da) 3-thiazol-4-yl-pyrolidinderivater som AMP-specifikke phosphodiesteraseinhibitorer
HK1054039B (zh) 取代的β-咔啉
MY135856A (en) Nicotinamide derivatives useful as pde4 inhibitors
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
MX2007006754A (es) Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
WO2005117979A3 (en) Use of il-17 in the treatment of fertility-related disorders
EP4100403A4 (en) 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONINERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
BR0209541A (pt) Uso das imidazotriazinonas 2-fenil-substituìdas
TW200612940A (en) Substituted tetrahydroisoquinolines as mmp inhibitors, process for their preparation and their use as medicament
GB0407025D0 (en) Novel compounds
NO20050146L (no) N,N-disubstituerte diazocykloalkaner nyttige i behandling av CNS-forstyrrelser grunnet serotonergisk dysfunksjon
TNSN05154A1 (en) Use of levocetirizine for the treatment of persistent allergic rhinitis
MY136138A (en) Hexacyclic compounds
EA200200750A1 (ru) Новое терапевтическое применение еноксапарина

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130425